Compare Stocks: EVGN, CARM, TPST, and BCDA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BCDA BioCardia	$1.08	$0.98	$0.75 ▼ $2.29	$16.35M	0.55	181,826 shs	57,265 shs
CARM Carisma Therapeutics	$0.00	$0.00	$0.00 ▼ $0.44	$29K	-9.02	63,196 shs	992 shs
EVGN Evogene	$0.54	$0.54	$0.37 ▼ $1.50	$4.69M	1.41	582,265 shs	62,829 shs
TPST Tempest Therapeutics	$1.03	$1.02	$0.84 ▼ $12.23	$17.04M	-1.68	304,717 shs	214,634 shs

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BCDA BioCardia	0.00%	-6.09%	+10.40%	+17.39%	-47.57%
CARM Carisma Therapeutics	0.00%	-46.15%	-72.00%	-96.32%	-99.83%
EVGN Evogene	0.00%	-2.13%	-10.36%	-7.74%	-55.29%
TPST Tempest Therapeutics	0.00%	-2.83%	+12.36%	-18.90%	-90.63%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BCDA BioCardia	$1.08	$0.98	$0.75 ▼ $2.29	$16.35M	0.55	181,826 shs	57,265 shs
CARM Carisma Therapeutics	$0.00	$0.00	$0.00 ▼ $0.44	$29K	-9.02	63,196 shs	992 shs
EVGN Evogene	$0.54	$0.54	$0.37 ▼ $1.50	$4.69M	1.41	582,265 shs	62,829 shs
TPST Tempest Therapeutics	$1.03	$1.02	$0.84 ▼ $12.23	$17.04M	-1.68	304,717 shs	214,634 shs

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BCDA BioCardia	0.00%	-6.09%	+10.40%	+17.39%	-47.57%
CARM Carisma Therapeutics	0.00%	-46.15%	-72.00%	-96.32%	-99.83%
EVGN Evogene	0.00%	-2.13%	-10.36%	-7.74%	-55.29%
TPST Tempest Therapeutics	0.00%	-2.83%	+12.36%	-18.90%	-90.63%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BCDA BioCardia	2.00	Hold	$25.00	2,214.81% Upside
CARM Carisma Therapeutics	1.00	Sell	N/A	N/A
EVGN Evogene	1.00	Sell	N/A	N/A
TPST Tempest Therapeutics	1.50	Reduce	N/A	N/A

Current Analyst Ratings Breakdown

Latest EVGN, CARM, TPST, and BCDA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/24/2026	BCDA BioCardia	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/11/2026	BCDA BioCardia	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
7/17/2026	BCDA BioCardia	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/13/2026	TPST Tempest Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/13/2026	BCDA BioCardia	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
7/8/2026	EVGN Evogene	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
6/9/2026	BCDA BioCardia	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$25.00

(Data available from 9/7/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BCDA BioCardia	$60K	272.52	N/A	N/A	$0.08 per share	13.50
CARM Carisma Therapeutics	$10.77M	0.00	N/A	N/A	($0.67) per share	0.00
EVGN Evogene	$3.85M	1.22	N/A	N/A	$1.37 per share	0.39
TPST Tempest Therapeutics	N/A	N/A	N/A	N/A	$1.35 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BCDA BioCardia	-$8.23M	-$0.64	N/A	N/A	N/A	N/A	-569.36%	-183.15%	11/11/2026 (Estimated)
CARM Carisma Therapeutics	-$60.48M	$0.73	0.00	N/A	N/A	-254.28%	N/A	-192.17%	11/5/2026 (Estimated)
EVGN Evogene	-$8.48M	-$0.91	N/A	N/A	N/A	-694.18%	-156.53%	-86.80%	11/18/2026 (Estimated)
TPST Tempest Therapeutics	-$26.26M	-$4.28	N/A	N/A	N/A	N/A	-576.56%	-134.99%	11/4/2026 (Estimated)

Latest EVGN, CARM, TPST, and BCDA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/13/2026	Q2 2026	TPST Tempest Therapeutics	-$0.30	-$0.34	-$0.04	-$0.34	N/A	N/A
8/12/2026	Q2 2026	BCDA BioCardia	-$0.18	-$0.13	+$0.05	-$0.13	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BCDA BioCardia	N/A	N/A	N/A	N/A	N/A
CARM Carisma Therapeutics	N/A	N/A	N/A	N/A	N/A
EVGN Evogene	N/A	N/A	N/A	N/A	N/A
TPST Tempest Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BCDA BioCardia	N/A	2.09	2.09
CARM Carisma Therapeutics	N/A	0.48	0.48
EVGN Evogene	N/A	3.57	3.54
TPST Tempest Therapeutics	N/A	0.38	0.38

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BCDA BioCardia	20.57%
CARM Carisma Therapeutics	44.27%
EVGN Evogene	10.40%
TPST Tempest Therapeutics	22.52%

Insider Ownership

Company	Insider Ownership
BCDA BioCardia	17.40%
CARM Carisma Therapeutics	6.90%
EVGN Evogene	7.40%
TPST Tempest Therapeutics	36.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BCDA BioCardia	40	15.14 million	12.51 million	Optionable
CARM Carisma Therapeutics	20	41.85 million	38.91 million	No Data
EVGN Evogene	140	8.72 million	8.07 million	No Data
TPST Tempest Therapeutics	20	16.54 million	10.55 million	No Data

EVGN, CARM, TPST, and BCDA Headlines

Recent News About These Companies

Tempest Therapeutics Announces Senlang Collaboration to Advance TPST-4003 In Vivo CAR-T Pipeline and Appoints Two New Directors

August 13, 2026 | quiverquant.comQ

Tempest Reports Second Quarter 2026 Financial Results and Provides Business Update

August 13, 2026 | globenewswire.com

Tempest Therapeutics: Tempest Announces Development Collaboration with Senlang Biotechnology for TPST-4003, a CD7-Targeted Next-Generation In Vivo CAR-T

July 21, 2026 | finanznachrichten.de

Tempest Therapeutics Announces Strategic Partnership with Senlang to Advance TPST-4003 into First-in-Human Study in Autoimmune Diseases

July 21, 2026 | quiverquant.comQ

Tempest Announces Development Collaboration with Senlang Biotechnology for TPST-4003, a CD7-Targeted Next-Generation In Vivo CAR-T

July 21, 2026 | globenewswire.com

Tempest Therapeutics Announces Advancement of Lead In Vivo CAR-T Candidate TPST-4003 into Planned Autoimmune Disease Trial

July 15, 2026 | quiverquant.comQ

Tempest Unveils Next-Generation In Vivo CAR-T Pipeline, with First Clinical Study Planned for the Fourth Quarter of 2026

July 15, 2026 | globenewswire.com

Tempest Therapeutics, Inc. Appoints Drake Richey and John Yee, MD, MPH to Board of Directors

June 4, 2026 | quiverquant.comQ

Tempest Therapeutics Appoints Drake Richey and John Yee, MD, MPH to Board of Directors

June 4, 2026 | globenewswire.com

Tempest Therapeutics Announces Resignation of Board Director

May 29, 2026 | tipranks.com

Tempest Therapeutics Announces Agreement for Warrant Exercise and New Short-Term Warrants

May 29, 2026 | quiverquant.comQ

Tempest Therapeutics Announces Warrant Exercise for Approximately $2 Million in Gross Proceeds

May 29, 2026 | globenewswire.com

Tempest Therapeutics Announces Multiple Board Director Resignations

May 22, 2026 | tipranks.com

Tempest Therapeutics: Tempest Reports First Quarter 2026 Financial Results and Provides Business Update

May 15, 2026 | finanznachrichten.de

Tempest Reports First Quarter 2026 Financial Results and Provides Business Update

May 14, 2026 | globenewswire.com

Tempest Presents Clinical Update at ISCT 2026 Annual Meeting

May 6, 2026 | globenewswire.com

Tempest to Advance Dual-Targeting CAR-T Platform with Clinical Update at ISCT 2026 Annual Meeting

April 29, 2026 | globenewswire.com

Tempest Announces Key Manufacturing Milestone for TPST-2003 Dual-Targeting CD19/BCMA CAR-T

April 22, 2026 | globenewswire.com

Tempest Appoints Andrew Fang, Ph.D., as Head of Business Development to Advance Strategic Partnerships and Global Licensing Efforts

April 14, 2026 | globenewswire.com

New Strong Buy Stocks for April 10th

April 10, 2026 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

EVGN, CARM, TPST, and BCDA Company Descriptions

BioCardia NASDAQ:BCDA

$1.08 0.00 (0.00%)

As of 09/4/2026 04:00 PM Eastern

BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. The company is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, it offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths. The company has collaboration agreements with CellProthera in the development of ProtheraCytes, which is currently under Phase II trial for the treatment of acute myocardial infarction. BioCardia, Inc. is based in Sunnyvale, California.

Carisma Therapeutics NASDAQ:CARM

$0.0007 0.00 (0.00%)

As of 09/4/2026 03:50 PM Eastern

Carisma Therapeutics, Inc., a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others. It is also developing in vivo CAR-M cell therapies in collaboration with Moderna Therapeutics to address multiple cancer targets; and multiple assets for the potential treatment of diseases beyond oncology, including fibrosis and other immunologic and inflammatory diseases. The company was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.

Evogene NASDAQ:EVGN

$0.54 0.00 (0.00%)

As of 09/4/2026 04:00 PM Eastern

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications. The Agriculture segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. Its products focus on various crops, such as corn, soybean, wheat, rice, and cotton. The Human Health segment discovers and develops human microbiome-based therapeutics for the treatment of immuno-oncology, GI related disorders, and antimicrobial resistance organisms. The Industrial Applications segment develops enhanced castor bean seeds to serve as a feedstock source for other industrial uses. The company also provides medical cannabis products. It operates in the United States, Israel, Brazil, and internationally. The company has strategic collaborations and licensing agreements with agricultural companies, such as BASF SE, Corteva, and Bayer. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel.

Tempest Therapeutics NASDAQ:TPST

$1.03 0.00 (0.00%)

As of 09/4/2026 04:00 PM Eastern

Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, an enzyme that regulates cGAS/STING pathway signaling and immune recognition. Tempest Therapeutics, Inc. was incorporated in 2011 and is headquartered in Brisbane, California. Tempest Therapeutics, Inc. operates as a subsidiary of Inception Sciences, Inc.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest EVGN, CARM, TPST, and BCDA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest EVGN, CARM, TPST, and BCDA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

EVGN, CARM, TPST, and BCDA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

EVGN, CARM, TPST, and BCDA Company Descriptions

BioCardia NASDAQ:BCDA

Carisma Therapeutics NASDAQ:CARM

Evogene NASDAQ:EVGN

Tempest Therapeutics NASDAQ:TPST

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest EVGN, CARM, TPST, and BCDA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest EVGN, CARM, TPST, and BCDA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

EVGN, CARM, TPST, and BCDA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

EVGN, CARM, TPST, and BCDA Company Descriptions

BioCardia NASDAQ:BCDA

Carisma Therapeutics NASDAQ:CARM

Evogene NASDAQ:EVGN

Tempest Therapeutics NASDAQ:TPST

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools